en · de · es · fr · pt
analytical-notes.peptides6823.com › Data › Cjc-1295 Structure And Mechanism — Reference Sheet

Cjc-1295 Structure And Mechanism — Reference Sheet

By Editorial Desk · published 2026-05-12 · last reviewed 2026-05-31 · Data

purity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-05-31 and is reviewed periodically as new material appears.

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.

Background and Naming Conventions

The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.

Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.

Cjc-1295 at a glance

PropertyValueNotes
Physical formLyophilized white powderSupplied as a freeze-dried solid for research use
Molecular weightApproximately 3,647 Da (DAC form)Lower for the variant lacking the albumin-binding moiety
SolubilitySoluble in water and aqueous bufferTypically dissolved in sterile or bacteriostatic water
Typical storage temperature−20 °C or belowDry powder, desiccated and protected from light
Common analytical methodReversed-phase HPLC with mass spectrometryUsed for purity estimation and identity confirmation

Albumin Binding and Duration of Action

Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.

The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.

Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.

Related pages on this site

Handling Storage and Quality Control

Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.

Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Reference notes

== History == Apixaban was approved for medical use in the European Union in May 2011. A new drug application (NDA) for the approval of apixaban was submitted to the US Food and Drug Administration (FDA) by Bristol-Myers Squibb (BMS) and Pfizer jointly after the conclusion of the ARISTOTLE clinical trial in 2011. Apixaban was approved for the prevention of stroke in people with atrial fibrillation in December 2012. In March 2014, it was approved for the additional indication of preventing deep vein thrombosis and pulmonary embolism in people who have recently undergone knee or hip replacement. In August 2014, the FDA approved apixaban for the additional indication of the treatment of recurring deep vein thrombosis and pulmonary embolism. During its development the drug was known as BMS-562247-01. By late 2019, sales of the product by BMS accounted for thirty percent of their quarterly revenue.

=== Animals cannot resynthesize carbohydrates from fatty acids === The main fuel stored in the bodies of animals is fat. A young adult human's fat stores average between about 15–20 kg (33–44 lb), but varies greatly depending on age, sex, and individual disposition. In contrast, the human body stores only about 400 g (0.9 lb) of glycogen, of which 300 g (0.7 lb) is locked inside the skeletal muscles and is unavailable to the body as a whole. The 100 g (0.2 lb) or so of glycogen stored in the liver is depleted within one day of starvation. Thereafter the glucose that is released into the blood by the liver for general use by the body tissues, has to be synthesized from the glucogenic amino acids and a few other gluconeogenic substrates, which do not include fatty acids. Fatty acids are broken down to acetyl-CoA by means of beta oxidation inside the mitochondria, whereas fatty acids are synthesized from acetyl-CoA outside the mitochondrion, in the cytosol. The two pathways are distinct, not only in where they occur, but also in the reactions that occur, and the substrates that are used. The two pathways are mutually inhibitory, preventing the acetyl-CoA produced by beta-oxidation from entering the synthetic pathway via the acetyl-CoA carboxylase reaction. It can also not be converted to pyruvate as the pyruvate decarboxylation reaction is irreversible. Instead it condenses with oxaloacetate, to enter the citric acid cycle.

=== Human health === Although there are only very few reported cases and epidemiological data, the FDA has set an action limit of 50 ppb in cider due to its potential carcinogenicity and other reported adverse effects. In humans, it was tested as an antiviral intranasally for use against the common cold with few significant adverse effects, yet also had negligible or no beneficial effect.

If you were to make it to heaven [...] you had to be interred correctly, for burial was the passage out of this world. The body had to be shrouded in the expectation that it would be reborn into eternal life. Then, on the eve of burial, the corpse had to be taken to church on a torch-lit bier and placed in the darkness of the nave, then laid in front of the high altar, surrounded by candles. The next day, in front of the whole community, a requiem mass was to be sung and the paschal candle lit [...]. Following this, there were prayers, hymns, special masses, and the body was borne to the grave, sprinkled with holy water and buried in consecrated ground. It must be laid head up with its feet to the east, for it was from this direction that Christ would return, from New Jerusalem, at the Apocalypse, when the worthy dead would be resurrected. [...] If burial rituals went awry, one's immortal soul was jeopardised. [...] Personal salvation – breaking free from the corporeal prison and ascending to a spiritual sphere unencumbered by materiality – is the logical culmination of the myth of humanity's supposed dominion over nature. [...].

Sources: en.wikipedia.org

Reference notes

Proteins are targeted for degradation by the proteasome with covalent modification of a lysine residue that requires the coordinated reactions of three enzymes. In the first step, a ubiquitin-activating enzyme (known as E1) hydrolyzes ATP and adenylylates a ubiquitin molecule. This is then transferred to E1's active-site cysteine residue in concert with the adenylylation of a second ubiquitin. This adenylylated ubiquitin is then transferred to a cysteine of a second enzyme, ubiquitin-conjugating enzyme (E2). In the last step, a member of a highly diverse class of enzymes known as ubiquitin ligases (E3) recognizes the specific protein to be ubiquitinated and catalyzes the transfer of ubiquitin from E2 to this target protein. A target protein must be labeled with at least four ubiquitin monomers (in the form of a polyubiquitin chain) before it is recognized by the proteasome lid. It is therefore the E3 that confers substrate specificity to this system. The number of E1, E2, and E3 proteins expressed depends on the organism and cell type, but there are many different E3 enzymes present in humans, indicating that there is a huge number of targets for the ubiquitin proteasome system. The ubiquitin protein itself is 76 amino acids long and was named due to its ubiquitous nature, as it has a highly conserved sequence and is found in all known eukaryotic organisms. The genes encoding ubiquitin in eukaryotes are arranged in tandem repeats, possibly due to the heavy transcription demands on these genes to produce enough ubiquitin for the cell.

==== Regulation in β cells ==== Glucose immediately amplifies glucokinase activity by the cooperativity effect. A second important rapid regulator of glucokinase activity in β cells occurs by direct protein-protein interaction between glucokinase and the "bifunctional enzyme" (phosphofructokinase-2/fructose-2,6-bisphosphatase), which also plays a role in the regulation of glycolysis. This physical association stabilizes glucokinase in a catalytically favorable conformation (somewhat opposite the effect of GKRP binding) that enhances its activity. In as little as 15 minutes, glucose can stimulate GCK transcription and glucokinase synthesis by way of insulin. Insulin is produced by the beta cells, but some of it acts on β cell B-type insulin receptors, providing an autocrine positive-feedback amplification of glucokinase activity. Further amplification occurs by insulin action (via A-type receptors) to stimulate its own transcription. Transcription of the GCK gene is initiated through the "upstream," or neuroendocrine, promoter. This promoter, in contrast to the liver promoter, has elements homologous to other insulin-induced gene promoters. Among the probable transacting factors are Pdx-1 and PPARγ. Pdx-1 is a homeodomain transcription factor involved in the differentiation of the pancreas. PPARγ is a nuclear receptor that responds to glitazone drugs by enhancing insulin sensitivity.

During periods of total war, the Army Reserve is incorporated by the royal prerogative into Regular Service under one code of Military Law for the duration of hostilities or until de-activation is decided upon. After the Second World War, for example, the Territorial Army, as it was known then, was not demobilised until 1947. Army Reservists normally have a full-time civilian job or career, which in some cases provides skills and expertise that are directly transferable to a specialist military role, such as NHS employees serving in Reservist Army Medical Services units. All Army Reserve personnel have their civilian jobs protected to a limited extent by law should they be compulsorily mobilised. There is, however, no legal protection against discrimination in employment for membership of the Army Reserve in the normal course of events (i.e. when not mobilised).

=== Zwitterion === Zwitterions contain an anionic and a cationic centre in the same molecule, but are not considered salts. Examples of zwitterions are amino acids, many metabolites, peptides, and proteins.

Human leukocyte antigen (HLA) B27 (subtypes B*2701-2759) is a class I surface molecule encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides (derived from self and non-self antigens) to T cells. HLA-B27 is strongly associated with ankylosing spondylitis and other associated inflammatory diseases, such as psoriatic arthritis, inflammatory bowel disease, and reactive arthritis.

Sources: en.wikipedia.org

Reference notes

Wild arapaima are harpooned or caught in large nets. Since the arapaima needs to surface to breathe air, traditional arapaima fishermen harpoon them and then club them to death. An individual fish can yield as much as 70 kg (150 lb) of meat. The arapaima was introduced for fishing in Thailand and Malaysia. Fishing in Thailand can be done in several lakes, where specimens over 150 kg (330 lb) are often landed and then released. On 14 May 2020, a 30 kg (66 lb) specimen was found floating in the river in Angkor Wat area, Krovanh village, Sangkat Norkor Thom, Siem Reap, Cambodia; the locals said it was a rare fish, and not commonly seen in this area. With catch-and-release after the fish is landed, it must be held for 5 minutes until it takes a breath. The fish has a large blood vessel running down its spine, so lifting the fish clear of the water for trophy shots can rupture this vessel, causing death.

Internalizing RGD (iRGD) peptides are a class of 9-amino acid cyclic peptides containing an RGD sequence, which undergo internalization as discussed below. The prototypic iRGD peptide, shown in the image on the right (sequence: CRGDKGPDC; CAS 1392278-76-0), was originally identified in an in vivo screening of phage display libraries in tumor-bearing mice. The peptide was able to home to tumor tissues, but in contrast to standard RGD (arginylglycylaspartic acid) peptides, spread much more extensively into extravascular tumor tissue. It was later identified that this extravasation and transport through extravascular tumor tissue is due to the bifunctional action of the molecule: after the initial RGD-mediated tumor homing, another pharmacologic motif is able to manipulate tumor microenvironment, making it temporarily accessible to circulating drugs. This second step is mediated through specific secondary binding to neuropilin-1 receptor, and subsequent activation of a trans-tissue pathway, dubbed the C-end Rule, or CendR pathway.

== Sources == Bulletins of the Information Bureau of the People's Union for the Defense of the Motherland and Freedom Savinkov, Boris. The Fight Against the Bolsheviks // Russian Foreign Literature. Anthology in Six Volumes. Moscow: Kniga, 1990. Vol. 1, Book 2. The Union for the Defense of the Homeland and Freedom and the Yaroslavl Rebellion of 1918 // Proletarian Revolution, 1923, no. 10. Klementyev, V. F. In Bolshevik Moscow (1918–1920). Moscow: Russkiy Put, 1998. Korovin, V. V.; Rusanov, E. P. Boris Savinkov's Case // History of the Soviet Union, 1967, no. 6, pp. 143–155. Golinkov, D. L. The Collapse of the Enemy Underground. Moscow, 1971. Gopper, Karl. Four Collapses: Memoirs of General Gopper. Riga, 1920. Jekabsons, E.; Ščerbinskis, V. Participation of Latvians in White Military Forces During the Russian Civil War 1917–1920. Riga: Journal of the Latvian Institute of History, 1997. Shentalinsky, Vitaly. "His Among His Own. Savinkov in the Lubyanka." New World, no. 7 (1996).

== History == The PUN was founded in 1957 as a political platform to support the presidential candidacy of "Papa Doc" Duvalier in the 1957 general election. In the aftermath of the July 1958 coup attempt, the Tonton Macoute — officially named Volunteers of the National Security (French: Volontaires de la Sécurité Nationale, VSN) — was formed as the paramilitary wing of the PUN. In 1963, other political parties in Haiti were outlawed, making the PUN the single political party of the nation. When "Papa Doc" Duvalier died in 1971, his son "Baby Doc" Duvalier succeeded him as the President of the country and the leader of the party. The party would remain in power until the fall and exile of "Baby Doc" Duvalier in 1986, at the height of the Anti-Duvalier protest movement, after which the party would enter a low profile stage, including the change of its name to National Progressive Party (French: Parti progressiste national, PPN). After the return of "Baby Doc" Duvalier from exile in 2011, the party began a process of reconstitution under its original name from 2014, and started opening departmental offices. Suffering a setback with the death of "Baby Doc" Duvalier in 2014, the party nominated Marc-Arthur Drouillard as its candidate in the 2015 presidential election. Towards that time, the legal representative of the party was Philomène Exe.

Sources: en.wikipedia.org

Frequently asked questions

How does CJC-1295 differ from modified GRF(1-29)?

The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.

Is CJC-1295 an approved medicine?

It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.

What is known about its half-life?

Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.

Does this compound occur naturally in the body?

No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.

Network